Low Acyl Gellan as an Excipient to Improve the Sprayability and Mucoadhesion of Iota Carrageenan in a Nasal Spray to Prevent Infection With SARS-CoV-2

The COVID-19 global pandemic, as well as the widespread persistence of influenza and the common cold, create the need for new medical devices such as nasal sprays to prevent viral infection and transmission. Carrageenan, a sulfated polysaccharide, has a broad, non-pharmacological antiviral capacity,...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in medical technology Vol. 3; p. 687681
Main Authors Robinson, Thomas E, Moakes, Richard J A, Grover, Liam M
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 16.06.2021
Subjects
antiviral polymer
carrageenan
COVID-19
gellan
Medical Technology
mucoadhesion
nasal spray
COVID-19
antiviral polymer
mucoadhesion
carrageenan
nasal spray
gellan
Online AccessGet full text

Cover

More Information
Summary:The COVID-19 global pandemic, as well as the widespread persistence of influenza and the common cold, create the need for new medical devices such as nasal sprays to prevent viral infection and transmission. Carrageenan, a sulfated polysaccharide, has a broad, non-pharmacological antiviral capacity, however it performs poorly in two key areas; spray coverage and mucoadhesion. Therefore gellan, another polysaccharide, was investigated as an excipient to improve these properties. It was found that viscoelastic relaxation time was the key predictor of spray coverage, and by reducing this value from 2.5 to 0.25 s, a mix of gellan and carrageenan gave more than four times the coverage of carrageenan alone ( < 0.0001). Gellan also demonstrated enhanced adhesion to a mucus analog that increased significantly with time ( < 0.0001), suggesting the development of specific gellan-mucin interactions. This property was conferred to carrageenan on mixing the two polymers. Together, this data suggests that gellan is a promising excipient to improve both sprayability and mucoadhesion of carrageenan for use in antiviral nasal sprays.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Diagnostic and Therapeutic Devices, a section of the journal Frontiers in Medical Technology
Edited by: Anthony Bull, Imperial College London, United Kingdom
Reviewed by: Canhui Yang, Southern University of Science and Technology, China; Kobra Omidfar, Tehran University of Medical Sciences, Iran
ISSN:2673-3129
2673-3129
DOI:10.3389/fmedt.2021.687681